Literature DB >> 1555136

Half-life and vitreous clearance of trifluorothymidine after intravitreal injection in the rabbit eye.

M P Pang1, R V Branchflower, A T Chang, G A Peyman, H Blatt, H K Minatoya.   

Abstract

To determine the half-life and vitreous clearance of trifluorothymidine, a drug that demonstrates good toxicity against cytomegalovirus (CMV), we injected 200 micrograms of the drug intravitreally in the eyes of nine New Zealand white rabbits. None of the rabbits showed any adverse reactions to the injection or the drug. The rabbits were killed at 3, 6, 12, 24 or 72 hours. High-performance liquid chromatography was used to measure the vitreous trifluorothymidine concentration. The half-life of the drug was found to be 3.15 hours, and the vitreous concentration remained above the ID50 (concentration required to inhibit cytopathic effects by 50% compared with control cultures) for CMV for about 30 hours. We conclude that trifluorothymidine may be of future benefit in the management of CMV retinitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1555136

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  4 in total

1.  Prediction of the vitreal half-life of small molecular drug-like compounds.

Authors:  Heidi Kidron; Eva M Del Amo; Kati-Sisko Vellonen; Arto Urtti
Journal:  Pharm Res       Date:  2012-07-10       Impact factor: 4.200

2.  Polyester-based microdisc systems for sustained release of neuroprotective phosphine-borane complexes.

Authors:  David A Janus; Christopher J Lieven; Megan E Crowe; Leonard A Levin
Journal:  Pharm Dev Technol       Date:  2017-06-09       Impact factor: 3.133

3.  Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR).

Authors:  Chandrasekar Durairaj; Jaymin C Shah; Shruti Senapati; Uday B Kompella
Journal:  Pharm Res       Date:  2008-10-08       Impact factor: 4.200

4.  Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes.

Authors:  Jeeyun Ahn; Hyuncheol Kim; Se Joon Woo; Ji Hyun Park; Sunyoung Park; Duck Jin Hwang; Kyu Hyung Park
Journal:  J Ocul Pharmacol Ther       Date:  2013-06-04       Impact factor: 2.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.